Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEN2L7)

Drug Name

AG019 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin-10 (IL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM0010	DMGMNUE	Pancreatic cancer	2C10	Phase 3	[2]
Ilodecakin	DMDNHRA	Sarcoidosis	4B20.5	Phase 2	[3]
F-8-IL-10 fusion protein	DMBFPO1	Endometriosis	GA10	Phase 2	[4]
XT-150	DMCYM9Q	Knee osteoarthritis	FA01	Phase 2	[5]
Ankinara	DMZKC7S	Inflammatory bowel disease	DD72	Investigative	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of ARMO BioSciences.
3	Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58.
4	Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.
5	Clinical pipeline report, company report or official report of Xalud Therapeutics
6	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.